Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus erythropoietin beta in transfusion-dependent low-risk or intermediate-1 myelodysplastic syndromes
2007-000972-18Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Aug 2007
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epoetin beta and azacitidine in myelodysplastic syndrome (MDS), sponsored by Fundación PETHEMA. Primary endpoint: Primary efficacy endpoints. Started Aug 2007; status: active.
02
Drugs
epoetin betaazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2007-000972-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000972-18.